Cronin C A, Weisman C J, Llinas R H
Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland 21224, USA.
Ann N Y Acad Sci. 2008 Oct;1142:159-78. doi: 10.1196/annals.1444.013.
For acute stroke patients who arrive at the hospital within 3 h of symptom onset, the focus of care involves screening for eligibility to receive intravenous tissue plasminogen activator. The publication of the National Institute of Neurological Disorders and Stroke recombinant tissue-type plasminogen activator (tPA, or alteplase) study in 1995 (Marler, J.R. 1995, New England Journal of Medicine333: 1581-1587) spurred protocol changes, which continue to evolve, throughout the health care system in an effort to streamline the patient through the Emergency Medical System. The need to expedite patient evaluation involving emergency department, laboratory, radiology, and clinical neurology testing is clear and has been a focus of many stroke centers. For some patients, intravenous thrombolysis within 3 h has a dramatic effect on outcome. However, that is not the only course of action for acute stroke patients. This article will review some of the effective treatments for stroke patients beyond the first 3 h of their care.
对于在症状发作后3小时内抵达医院的急性中风患者,护理重点在于筛查是否有资格接受静脉注射组织型纤溶酶原激活剂。1995年美国国立神经疾病与中风研究所重组组织型纤溶酶原激活剂(tPA,即阿替普酶)研究的发表(Marler, J.R. 1995,《新英格兰医学杂志》333: 1581 - 1587)促使整个医疗系统的方案发生改变,这些改变仍在不断演变,旨在通过紧急医疗系统简化患者就诊流程。加快涉及急诊科、实验室、放射科和临床神经学检测的患者评估的必要性是明确的,并且一直是许多中风中心关注的焦点。对于一些患者而言,3小时内进行静脉溶栓对治疗结果有显著影响。然而,这并非急性中风患者的唯一治疗方案。本文将回顾在中风患者护理最初3小时之后的一些有效治疗方法。